Aptevo Therapeutics Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.45% | -4.51% | 8.02% | -47.99% | -5.46% |
| Total Depreciation and Amortization | -34.69% | -42.62% | 14.08% | -41.67% | -46.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 198.18% | -27.59% | 6.13% | -48.32% | -59.71% |
| Change in Net Operating Assets | 151.72% | -139.50% | -10.26% | 307.63% | -65.30% |
| Cash from Operations | 23.11% | -21.14% | 9.08% | -28.07% | -15.28% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.95% | -- | -7.27% | 273.58% | 261.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.95% | -- | -13.78% | 273.58% | 261.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -165.03% | -7.89% | -41.94% | 3,822.36% | 432.92% |